L
Lineage Cell Therapeutics D
D
LCTX
1.56000
USD
-0.03
(-1.58%)
مغلق
حجم التداول
12,763
الربح لكل سهم
-0
العائد الربحي
-
P/E
-6
حجم السوق
388,576,545
المقالات
العنوان: Lineage Cell Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
